FOSTER CITY, Calif. — Gilead Sciences Inc. said Monday that the Food and Drug Administration rejected two marketing applications for HIV treatments, citing quality control problems at the company's manufacturing facilities.
The FDA informed the company in a letter that it cannot approve its HIV pills elvitegravir and cobicistat for use in managing the virus that causes AIDS.
The agency noted that in recent inspections regulators have found problems with documentations and quality testing at Gilead Sciences' facilities.
The company said in a news release it is working to address the issues raised by the agency. A message was left with the company seeking more details on the quality control problems.
Elvitegravir and cobicistat are already approved as ingredients in Gilead's four-in-one HIV pill Stribild, which was approved by FDA in August 2012 for adults who have not yet been treated with anti-HIV drugs.
Gilead asked the FDA to approve the drugs as stand-alone treatments in June. The company is also seeking approval in Europe.
Its shares fell 22 cents to $51.16 in morning trading Monday. Its shares peaked for the past year at $55.16 last Tuesday. They traded as low as $24.12 in early June 2012.
Anda sedang membaca artikel tentang
FDA rejects 2 HIV drugs from Gilead Sciences
Dengan url
http://newsreviewsis.blogspot.com/2013/04/fda-rejects-2-hiv-drugs-from-gilead.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
FDA rejects 2 HIV drugs from Gilead Sciences
namun jangan lupa untuk meletakkan link
FDA rejects 2 HIV drugs from Gilead Sciences
sebagai sumbernya
0 komentar:
Posting Komentar